Log in
Donate
Search
Close this search box.

Clinical Trial: ECOG-ACRIN EA9161

ECOG-ACRIN EA9161

Status: Closed

NCT#03701282

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic

EA9161 is closed to new accrual effective April 30, 2021.

View All Clinical Trials
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved